Clinical, biological and histological characteristics of bullous pemphigoid associated with anti‐PD‐1/PD‐L1 therapy: A national retrospective study

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

James Larkin, Vanna Chiarion‐Sileni, René González et al. · New England Journal of Medicine · 2015 · 8.1K citations · Full text

Life Sciences, Oncology, Pharmacotherapy +17

Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation

Caroline Robert, Georgina V. Long, Benjamin Brady et al. · New England Journal of Medicine · 2014 · 5.4K citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1

Jarushka Naidoo, Katja Schindler, Christiane Querfeld et al. · Cancer Immunology Research · 2016 · 283 citations · Full text

Life Sciences, Dermatology, Oncology +17

Bullous disorders associated with anti–PD-1 and anti–PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy

Jacob Siegel, Mariam Totonchy, William Damsky et al. · Journal of the American Academy of Dermatology · 2018 · 204 citations

Medicine, Oncology, Pathology +17

Management of immune checkpoint inhibitor–induced bullous pemphigoid

Zoé Apalla, Aimilios Lallas, Florentina Delli et al. · Journal of the American Academy of Dermatology · 2020 · 32 citations · Full text

Life Sciences, Immunology, Pathology +14